Precision NanoSystems (Cytiva)
Vancouver, BC
Reagent / Material Supplier
Program data pending ClinicalTrials.gov matching
· Last scored 2026-04-02
69.0
Signal Score
○ FDA Inspections
○ Clinical Trials
✓ SEC Filings (13)
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: Precision NanoSystems (Cytiva)
- Signal Score
- 69.0/100 (as of 2026-04-02)
- Quality Compliance
- Assessment pending
- Headquarters
- Vancouver, BC
- Modalities
- mRNA
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesmRNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
72.0
Moderate industry presence in SEC filings (45 mentions)
Major facility investment disclosed in SEC filings
Multiple manufacturing risk factors in SEC filings
Source: SEC EDGAR, press monitoring
13 SEC filings with industry mentions on record
SEC Filings13 with industry mentions
Moderate industry presence in SEC filings (45 mentions)
Major facility investment disclosed in SEC filings
Multiple manufacturing risk factors in SEC filings
Capacity
66.0
10 facility investment mentions in SEC filings
Sites: Vancouver, BC
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
10 facility investment mentions in SEC filings
Financial Intelligence
"government could also control our allocation of manufacturing capacity."
"These therapeutics include protein-based and other biological therapies as well as a new emerging class of highly-targeted therapies such as cell and gene therapies and nucleic acid-based therapies."
"Typical users of these products and services include pharmaceutical and biopharmaceutical companies, translational medicine institutions, biotechnology companies and contract manufacturing organizations."
"government could also control our allocation of manufacturing capacity."
"LIFE SCIENCES
The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for the manufacture of instruments that are used in OTL arrangements that certain of the Company’s businesses enter into with customers, increasing manufacturing capacity, replacing equipment, purchasing facilities, supporting new product development and improving IT systems."
"government could also control our allocation of manufacturing capacity."
"29
Table of Contents
LIFE SCIENCES
The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for increasing manufacturing capacity, the manufacture of instruments that are used in OTL arrangements that certain of the Company’s businesses enter into with customers, replacing equipment, purchasing facilities, supporting new product development and improving IT systems."
"government could also control our allocation of manufacturing capacity."
"LIFE SCIENCES
The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for increasing manufacturing capacity, the manufacture of instruments that are used in OTL arrangements that certain of the Company’s businesses enter into with customers, replacing equipment, purchasing facilities, supporting new product development and improving IT systems."
"government could also control our allocation of manufacturing capacity."
"These therapeutics include protein-based and other biological therapies as well as a new emerging class of highly-targeted therapies such as cell and gene therapies and nucleic acid-based therapies."
"Typical users of these products and services include pharmaceutical and biopharmaceutical companies, translational medicine institutions, biotechnology companies and contract manufacturing organizations."
"government could also control our allocation of manufacturing capacity."
"LIFE SCIENCES
The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for increasing manufacturing capacity, replacing equipment, the manufacture of instruments that are used in OTL arrangements that certain of the Company’s businesses enter into with customers, supporting new product development and improving IT systems."
"government could also control our allocation of manufacturing capacity."
"Additionally, while the Company believes that emerging biotech customers are continuing to manage their liquidity, we also believe they are prioritizing select cell and gene therapy projects, and we further believe that the improvement in the overall funding environment in the period is a positive leading indicator for these customers."
"LIFE SCIENCES
The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"government could also control our allocation of manufacturing capacity."
"LIFE SCIENCES
The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies."
"Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for increasing manufacturing capacity, replacing equipment, the manufacture of instruments that are used in OTL arrangements that certain of the Company’s businesses enter into with customers, supporting new product development and improving IT systems."
Source: SEC EDGAR · Retrieved Apr 05, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Evonik Health Care
Birmingham, AL · Vancouver, BC
Signal Score: 81.5
mRNA, Biologics
Acuitas Therapeutics
Vancouver, BC
Signal Score: 56.5
mRNA
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
Signal Score: 91.5
Biologics, mRNA
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 88.0
AAV, Lentiviral, Plasmid, mRNA
BioNTech (Mfg Services)
Mainz, DE · Marburg, DE
Signal Score: 84.8
mRNA